FIR haplodeficiency promotes splicing to pyruvate kinase M2. According to a study published on Oncotarget Journal, the results was achieved using six-plex tandem mass tag quantitative proteomic analysis in the thymic lymphoma tissues of mice. The paper was published on the issue No. 40, Volume 8 of the journal. Watch this video on Youtube.
The study was prompted with the importance of converting pyravate kinase M1 to PKM2 during metabolism of glucose. PKM2 is found in cancer tissue while PKM1 is found in normal tissues. This study reveals the role of haplodeficiency of FUSE-binding protein-interacting repressors (FIR) in the process. The study further revealed that cancers were not able to regulate PKM2 yet they were still able to regulate PKM1. The research, which was conducted by a team of scientists that included Asako Kimura, Nokuko Tanaka, and Toshinari Minamoto, also revealed that the conversion of PKM1 to PKM2 was higher in mice tissues that were FIR+/-TP53-/-. In addition, the researchers concluded from the research that FIR and its spliceosomes could form ideal targets for targeted cancer therapies. The spliceosomes includes T-ALL. This information was originally reported on Research Gate as explained in this link https://www.researchgate.net/publication/320295957_oncotarget-08-67955
In other news, Oncotarget has increased the number of the issues it publishes from one to two every week. This is in response to the increasing number of researchers and scientists who are requesting the journal to publish their works. The journal will continue to remain open-source and will be available to any medicine enthusiast to read from a number of platforms. The platforms are mainly high profile scientific indexes and archives. They include BOISIS Previews, EMBASE, Biological Abstracts, Scopus, Science Citation Index Expanded, PubMed, PubMed Central, and ISI/Wed of Science. Oncotarget will also work closely with the National Library of Medicine to submit its issues to PubMed. This collaboration will greatly reduce the number of days it takes to publish the issues. Learn more about Oncotarget at Eurekalert.org.
Oncotarget is a peer-reviewed open access bio-medical journal. The publication covers all aspects of oncology, including topics such as autophagy, pathology and chromosomes, aging, and immunology and microbiology. Since its launch in 2010, the journal has published almost four hundred issues. Its first seven volumes had 324 issues. The increase of Oncotarget’s publication frequency will see the number of issues it publishes per year increase from 52 to over 104 issues.